SLAMF1/CD150 receptor is a founder of signaling lymphocyte activation molecule (SLAM) family of cell-surface receptors. It is widely expressed on cells within hematopoietic system. In hematologic malignancies CD150 cell surface expression is restricted to cutaneous T-cell lymphomas, few types of B-cell non-Hodgkin's lymphoma, near half of cases of chronic lymphocytic leukemia, Hodgkin's lymphoma, and multiple myeloma. Differential expression among various types of hematological malignancies allows considering CD150 as diagnostical and potential prognostic marker. Moreover, CD150 may be a target for antibody-based or measles virus oncolytic therapy. Due to CD150 signaling properties it is involved in regulation of malignant cell fate decision and tumor microenvironment in Hodgkin's lymphoma and chronic lymphocytic leukemia. This review summarizes evidence for the important role of CD150 in pathogenesis of hematologic malignancies.

SLAMF1 / CD150受体是细胞表面受体信号转导淋巴细胞激活分子（SLAM）家族的奠基人。它在造血系统内的细胞上广泛表达。在血液系统恶性肿瘤中，CD150细胞表面表达仅限于皮肤T细胞淋巴瘤，少数类型的B细胞非霍奇金淋巴瘤，近一半的慢性淋巴细胞性白血病，霍奇金淋巴瘤和多发性骨髓瘤。各种类型的血液系统恶性肿瘤之间的差异表达使CD150可作为诊断和潜在的预后标志物。此外，CD150可能是基于抗体或麻疹病毒溶瘤治疗的靶标。由于CD150的信号传导特性，它参与了霍奇金淋巴瘤和慢性淋巴细胞性白血病的恶性细胞命运决定和肿瘤微环境的调节。